文献速递前列腺增生与排尿功能障碍

别嘌呤醇与芬兰人群良性前列腺增生风险的前瞻性队列研究

Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-12-22

该研究基于芬兰前列腺癌筛查研究(FinRSPC)74,754名男性的人群队列,分析别嘌呤醇使用与良性前列腺增生(BPH)三个终点(启动BPH药物、BPH诊断、BPH相关手术)的关联。多变量调整后,使用别嘌呤醇与三个BPH终点风险降低相关,风险降低仅在BMI高于中位数(27.3 kg/m2)的男性中观察到,且滞后1-2年后风险降低消失。

要点

  • 别嘌呤醇使用与BPH药物治疗(HR 0.81)、BPH诊断(HR 0.78)和BPH相关手术(HR 0.67)风险降低相关。
  • 风险关联不随累积使用量改变,滞后1-2年后风险降低消失。
  • 仅BMI高于中位数(27.3 kg/m2)的男性中观察到风险降低(交互作用P<0.05)。

核心结论

  • 别嘌呤醇使用与BPH药物治疗、诊断和手术风险降低相关,可能的解释是别嘌呤醇的抗氧化作用。

研究设计与样本

  • 研究队列由芬兰前列腺癌筛查研究(FinRSPC)中最初识别的74,754名男性组成,排除基线有BPH记录的男性,采用Cox回归分析,药物使用作为时变变量。

主要发现

  • 多变量调整后,使用别嘌呤醇的男性BPH药物治疗风险降低(HR 0.81;95% CI 0.75-0.88),BPH诊断风险降低(HR 0.78;95% CI 0.71-0.86),BPH相关手术风险降低(HR 0.67;95% CI 0.58-0.76)。
  • 风险关联不随累积使用量改变;滞后1-2年后风险降低消失。
  • 仅BMI高于中位数(27.3 kg/m2)的男性中观察到风险降低,交互作用P<0.05(每个终点)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic syndrome and obesity are linked with hyperuricemia, and it has also been proposed that oxidative stress associated with hyperuricemia may promote benign prostatic hyperplasia (BPH). However, it is currently unknown whether use of antihyperuricemic medication is associated with risk of developing BPH. We studied the association between BPH and use of antihyperuricemic allopurinol in a Finnish population-based cohort. METHODS: The study cohort consisted of 74,754 men originally identified for the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Information on gout and BPH medication usage (5α-reductase inhibitors, 5ARIs) during 1996-2014 was obtained from the National medication reimbursement database. Information on BPH diagnoses from in- and outpatient hospital visits and BPH-related surgery was obtained from the National Health Care Registry. Men with a record of BPH at baseline was excluded. We used Cox regression to analyze risk of starting BPH medication, having a recorded diagnosis or undergoing BPH surgery by allopurinol use with adjustment for age and simultaneous use of statins, antidiabetic or antihypertensive drugs and aspirin or other NSAIDs. Medication use was analyzed as a time-dependent variable to minimize immortal time bias. RESULTS: Men using allopurinol had a decreased risk for all three BPH endpoints: BPH medication (HR 0.81; 95% CI 0.75-0.88), BPH diagnosis (HR 0.78; 95% CI 0.71-0.86) and BPH-related surgery (HR 0.67; 95% CI 0.58-0.76) after multivariable adjustment. The risk association did not change by cumulative use. The risk decrease disappeared after 1-2 years lag time. Only BMI modified the risk association; the risk decrease was observed only among men with BMI above the median (27.3 kg/m2); p for interaction <0.05 for each endpoint. CONCLUSIONS: We found that allopurinol use is associated with lowered risk of BPH medication, diagnosis and surgery. A possible explanation could be antioxidative effects of urate-lowering allopurinol.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Kukko V, Kaipia A, Talala K, et al. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2017. PMID: 29273728. doi:10.1038/s41391-017-0031-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。